EMCDDA Home
  • EN
Search

Harm reduction overview for Slovakia

Map of Slovakia

1. National context

Low-threshold services and outreach harm reduction programmes in Slovakia provide access to clean needles and syringes (mainly through exchange) and information on safer drug use, although coverage is limited — an estimated 21 % of problem drug users could be reached by existing low-threshold services. Because of this, public pharmacies remain the main source of clean needles and syringes in Slovakia. In 2013 five organisations ran outreach needle, and needle and syringe, exchange programmes (NSPs), in five towns. Three towns — Bratislava, Banská Bystrica and Košice — had both mobile/outreach and stationary syringe exchange programmes. According to data from independent exchange programmes provided by field services and treatment institutions, a total of 321 000 syringes were provided in 2013. The majority of harm reduction programme clients were methamphetamine (pervitin) users, while the proportion of those who inject heroin has declined. Testing for infectious diseases among drug users who are not in contact with healthcare units (in treatment) is not regularly available, and most harm reduction organisations provide testing only occasionally.

top of page

2. Responses to prevent and reduce drug-related infectious diseases

Needle and syringe programmes Country  data
Availability of  NSP programmes  Extensive
% NSP availability at NUTS3  63 %
Drug use equipment distributed at specialised drug agencies (standard prevention material)
availability of alcohol pads  Yes
availability of dry wipes  Yes
availability of containers  Yes
availability of water  Yes
availability of condoms  Yes
availability of foil  Yes

Sources:

Structured questionnaire 'Prevention and reduction of health-related harm associated with drug use' (SQ23/29), submitted in 2014.
For an explanation of terms used, see the definitions of terms.
Availability expert rating scale:

  • Full – nearly all persons in need would obtain it.
  • Extensive – a majority but not nearly all of them would obtain it.
  • Limited – more than a few but not a majority of them would obtain it.
  • Rare – just a few of them would obtain it.
Testing, vaccination and treatment of infections Country  data
Availability of Hepatitis C testing in the community  Limited
Availability of universal hepatitis B immunization programme  Yes
Hepatitis B vaccination programme specific for high risk groups  No
ARV treatment of HIV infection  :

Sources:

Structured questionnaire 'Prevention and reduction of health-related harm associated with drug use' (SQ23/29), submitted in 2014.
Availability expert rating scale:

  • Full – nearly all persons in need would obtain it.
  • Extensive – a majority but not nearly all of them would obtain it.
  • Limited – more than a few but not a majority of them would obtain it.
  • Rare – just a few of them would obtain it.
Health promotion responses Country  data
Availability of individual counselling programmes  Extensive
Availability of programmes for practical advice and training on 'safer use/safer injecting'  Limited
Involvement of peer educators in the response to infectious diseases prevention  Yes

Sources:

Structured questionnaire 'Prevention and reduction of health-related harm associated with drug use' (SQ23/29), submitted in 2014.
Availability expert rating scale:

  • Full – nearly all persons in need would obtain it.
  • Extensive – a majority but not nearly all of them would obtain it.
  • Limited – more than a few but not a majority of them would obtain it.
  • Rare – just a few of them would obtain it.

Drug Treatment

See the country specific treatment profile.

top of page

3. Responses to prevent and reduce drug-related deaths

Availability of drug-related death responses in the community Country  data
Availability of overdose information materials  Limited
Availability of individual overdose risk assessment (provided by trained drugs or health workers)  Rare
Availability of overdose response training  Limited

Sources:

Structured questionnaire 'Prevention and reduction of health-related harm associated with drug use' (SQ23/29), submitted in 2014.
Availability expert rating scale:

  • Full – nearly all persons in need would obtain it.
  • Extensive – a majority but not nearly all of them would obtain it.
  • Limited – more than a few but not a majority of them would obtain it.
  • Rare – just a few of them would obtain it.
Availability of drug consumption rooms Country  data
Number of facilities n.av.
Number of cities n.av.
Number of consumptions per year n.av.

Sources:

Structured questionnaire 'Prevention and reduction of health-related harm associated with drug use' (SQ23/29), submitted in 2011.
N.Av. stands for ‘The intervention is not available in the country’.

top of page

4. Responses to prevent and reduce drug-related harms in recreational settings

Provision of specific responses implemented in night clubs and festivals Free, accessible, cold water Immediate First Aid ‘Chill out’ rooms Information material Outreach work Amnesty bins
Night clubs  Rare : : Rare Limited Does not exist
Festivals  Rare Full Limited Extensive Extensive Does not exist

Sources:

Structured questionnaire 'Prevention and reduction of health-related harm associated with drug use' (SQ23/29), submitted in 2011.
Provision expert rating scale:

  • Full – in nearly all night clubs/festivals.
  • Extensive – a majority of night clubs/festivals provide the intervention (but not nearly all of them).
  • Limited – more than a few night clubs/festivals provide the intervention (but not a majority of them).
  • Rare – just a few night clubs/festivals provide the intervention.

top of page

5. References and links

Related EMCDDA resources

 

About the EMCDDA

The European Monitoring Centre for Drugs and Drug Addiction (EMCDDA) is the reference point on drugs and drug addiction information in Europe. Inaugurated in Lisbon in 1995, it is one of the EU's decentralised agencies. Read more >>

Contact us

EMCDDA
Praça Europa 1, Cais do Sodré
1249-289 Lisbon
Portugal
Tel. (351) 211 21 02 00
Fax (351) 218 13 17 11

More contact options >>

Page last updated: Wednesday, 03 June 2015